Patents by Inventor Naoya Tsurushita

Naoya Tsurushita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CCR5 antibody
    Publication number: 20080107595
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii), two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Application
    Filed: October 16, 2006
    Publication date: May 8, 2008
    Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Patent number: 7365168
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: April 29, 2008
    Assignee: PDL BioPharma, Inc.
    Inventors: Paul Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Patent number: 7361740
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: April 22, 2008
    Assignee: PDL BioPharma, Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez
  • Treatment Of Inflammatory Bowel Diseases With Anti-Ip-10 Antibodies
    Publication number: 20080063646
    Abstract: The present invention is directed to high affinity anti-human IP-10 antibodies or antigen-binding fragments of these antibodies, including chimeric, humanized or fully human antibodies. The present invention is also directed to a method of reducing the severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof comprising administering to said subject an effective amount of an antagonist of IP-10, including the antibodies or antibody fragments of the present invention.
    Type: Application
    Filed: November 10, 2004
    Publication date: March 13, 2008
    Inventors: Balaji Balasa, Naoya Tsurushita, Nicholas F. Landolfi
  • Humanized anti-?antibodies
    Patent number: 7318923
    Abstract: Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: January 15, 2008
    Assignee: Eli Lilly and Company
    Inventors: Naoya Tsurushita, Maximiliano J. Vasquez
  • Amphiregulin antibodies and their use to treat cancer and psoriasis
    Patent number: 7223393
    Abstract: The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: May 29, 2007
    Assignee: PDL Biopharma, Inc
    Inventors: Nicholas F. Landolfi, Naoya Tsurushita, Paul R. Hinton, Shankar Kumar
  • Alteration of Fc-fusion protein serum half-lives by mutagenesis
    Patent number: 7217798
    Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: May 15, 2007
    Assignee: PDL BioPharma, Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Patent number: 7217797
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: May 15, 2007
    Assignee: PDL Biopharma, Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez
  • Humanized antibodies that sequester abeta peptide
    Patent number: 7195761
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13–28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: March 27, 2007
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Humanized antibodies to gamma-interferon
    Patent number: 7183390
    Abstract: The invention provides humanized immunoglobulins that bind to and neutralize ?-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: February 27, 2007
    Assignee: PDL BioPharma, Inc.
    Inventors: Maximiliano Vasquez, Nicholas F. Landolfi, Naoya Tsurushita, Cary L. Queen
  • Anti-CCR5 antibody
    Publication number: 20070031408
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Application
    Filed: October 16, 2006
    Publication date: February 8, 2007
    Inventors: William Olson, Paul Maddon, Naoya Tsurushita, Paul Hinton, Maximillano Vasquez
  • Anti-CCR5 antibody
    Patent number: 7122185
    Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg4:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg4:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: October 17, 2006
    Assignees: Progenics Pharmaceuticals, Inc., PDL Biopharma, Inc.
    Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximillano Vasquez
  • Antibodies against CTLA4 and uses therefor
    Publication number: 20060165706
    Abstract: The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.
    Type: Application
    Filed: December 29, 2005
    Publication date: July 27, 2006
    Applicant: Genetics Institute, LLC
    Inventors: Beatriz Carreno, Clive Wood, Katherine Turner, Mary Collins, Gary Gray, Donna Morris, Denise O'Hara, Paul Hinton, Naoya Tsurushita
  • Antibodies against CTLA4
    Patent number: 7034121
    Abstract: The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: April 25, 2006
    Assignee: Genetics Institue, LLC
    Inventors: Beatriz M. Carreno, Clive Wood, Katherine Turner, Mary Collins, Gary S. Gray, Donna Morris, Denise O'Hara, Paul R. Hinton, Naoya Tsurushita
  • Humanized antibodies that sequester abeta peptide
    Publication number: 20060039906
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Application
    Filed: September 12, 2005
    Publication date: February 23, 2006
    Inventors: David Holtzman, Ronald DeMattos, Kelly Bales, Steven Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Publication number: 20050276799
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Application
    Filed: April 8, 2005
    Publication date: December 15, 2005
    Inventors: Paul Hinton, Naoya Tsurushita, J. Tso, Maximiliano Vasquez
  • Alteration of Fc-fusion protein serum half-lives by mutagenesis
    Publication number: 20050226864
    Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
    Type: Application
    Filed: October 15, 2004
    Publication date: October 13, 2005
    Inventors: Paul Hinton, Naoya Tsurushita
  • Humanized antibodies
    Publication number: 20050090648
    Abstract: Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.
    Type: Application
    Filed: April 26, 2002
    Publication date: April 28, 2005
    Inventors: Naoya Tsurushita, Maximiliano Vasquez
  • Interleukin-1 beta antibodies
    Publication number: 20050075488
    Abstract: The present invention encompasses high affinity antibodies that neutralize IL-1? activity in vivo. These antibodies can be used to treat various diseases such as rheumatoid arthritis and osteoarthritis.
    Type: Application
    Filed: July 18, 2002
    Publication date: April 7, 2005
    Inventors: Stuart Bright, Audrey Jia, Stuart Kuhstoss, Joseph Vincent Manetta, Naoya Tsurushita, Maximiliano Vasquez
  • Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
    Publication number: 20050032114
    Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
    Type: Application
    Filed: October 15, 2003
    Publication date: February 10, 2005
    Inventors: Paul Hinton, Naoya Tsurushita, J. Tso, Maximiliano Vasquez